During a mid-March scientific and policy meeting, a group of cadets from the United States Military Academy at West Point - none biology or pre-med majors - stood before a group of leading international pediatric cancer researchers, representatives from major biopharmaceutical companies, and officials from government agencies like the National Cancer Institute, U.S. Food and Drug Administration, and the European Medicines Agency, and told their distinguished audience - many double their age and far more than double their experience in the field - how they could work together to overcome the barriers to pediatric cancer drug development.

The cadets were presenting preliminary findings from their project "Confronting the Impediments to Pediatric Brain Tumor Treatment Development" during the Pediatric Brain Tumor and Cancer Drug Development Working Group, hosted by the National Brain Tumor Society in Washington, D.C.

Now, the cadets have wrapped up their project, and are ready to let the community know about their exciting plan to help move the field of pediatric brain tumor and cancer research forward. Read more about the intriguing conclusions from the cadets' report.

The issue of “acquired resistance” has become a much-discussed topic in recent years within the oncology field. This is one of the single biggest challenges in treating brain tumors. Read More

This year, National Brain Tumor Society leveraged the focus on BTAM to share research, policy and resources with the community, as well as invite the community to share your own experiences and knowledge in return. The results were overwhelmingly positive. Read More